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Background: The mechanisms by which T cell receptors (TCRs) engage lengthy peptides bound to human leukocyte
antigens (HLA) is unclear.
Results:We have determined the structures of two TCRs binding to a 13-residue bulged peptide presented by HLA-B*35:08.
Conclusion: TCRs can adopt markedly differing docking strategies upon engaging lengthy bulged peptides.
Significance: The human T-cell repertoire is sufficiently robust to deal with viral determinants of atypical length.
Human leukocyte antigen (HLA)-I molecules can present
long peptides, yet the mechanisms by which T-cell receptors
(TCRs) recognize featured pHLA-I landscapes are unclear. We
compared the binding modes of three distinct human TCRs,
CA5, SB27, and SB47, complexed with a “super-bulged” viral
peptide (LPEPLPQGQLTAY) restricted by HLA-B*35:08. The
CA5andSB27TCRs engagedHLA-B*35:08LPEP similarly, strad-
dling the central region of the peptide but making limited con-
tactswithHLA-B*35:08. Remarkably, theCA5TCRdidnot con-
tact the 1-helix of HLA-B*35:08. Differences in the CDR3
loop between the CA5 and SB27 TCRs caused altered fine spec-
ificities. Surprisingly, the SB47 TCR engaged HLA-B*35:08LPEP
using a completely distinct binding mechanism, namely
“bypassing” the bulged peptide and making extensive contacts
with the extremeN-terminal end ofHLA-B*35:08. This docking
footprint included HLA-I residues not observed previously as
TCR contact sites. The three TCRs exhibited differing patterns
of alloreactivity toward closely related or distinct HLA-I allo-
types. Thus, the human T-cell repertoire comprises a range of
TCRs that can interact with “bulged” pHLA-I epitopes using
unpredictable strategies, including the adoption of atypical
footprints on the MHC-I.
Clonally distributed  T-cell receptors (TCRs)8 on CD8
cytotoxic T lymphocytes (CTLs) specifically recognize peptide
(p) fragments, generally between 8 and 10 amino acids in
length, presented by major histocompatibility complex class I
(MHC-I) molecules expressed on the surface of all nucleated
cells (1). TCR recognition of pMHC-I complexes is a key event
in cellular immunity that is central to thymic selection (2), the
lysis of pathogen-infected cells and the eradication of cancer-
ous tissue. In general, TCR recognition is genetically restricted
to self-MHCmolecules, although the underlying basis of MHC
restriction remains unclear (3–5). Puzzlingly, a relatively high
frequency of T-cells break the “MHC restriction code” and rec-
ognize non-self (“allo”) human leukocyte antigen class I
(HLA-I) molecules (6). The molecular mechanisms underpin-
ning T-cell alloreactivity, a cause of T-cell-mediated transplant
rejection, are beginning to emerge (7–9).
Structural studies have shed insight on the nature of the
TCR-pMHC-I interaction (for recent reviews, see Refs. 3–5, 10,
and 11). The TCR comprises six complementarity-determining
regions (CDRs), whereby the germline-encoded CDR1/2 loops
arise from the TRAV or TRBV genes (12), whereas the CDR3
loops lie at the V, (D), and J region junction, fromwhich greater
diversity is generated by random nucleotide (N) deletions and
non-templated additions. TCRs can bind differing and identical
pMHC-I epitopes using a range of docking modes (5, 7, 13).
Within such TCR-pMHC-I complexes, the CDR loops of the
TCR engage pMHC-I to varying extents (14). Despite these
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variations on a theme, a broad consensus TCR-pMHC-I foot-
print is conserved in which the V and V domains of the TCR
sit over the MHC-I 2- and 1-helices, respectively. The short
antigenic peptide fragments generally protrudeminimally from
theMHC-I cleft, such that the TCRmostly contacts theMHC-I
molecule. Nevertheless, associated mutagenesis studies in a
number of TCR-pMHC-I systems have shown that generally
only a few residues of the MHC-I (termed the “hot spots”)
contribute significantly to the energetics of the TCR-
pMHC-I interaction; moreover, such hot spots can vary
between different TCR-pMHC-I systems (15–21). Such
investigations highlight the peptide-centric nature of the
TCR-pMHC-I interaction.
Although the N- and C-terminal ends of the MHC-I binding
cleft constrain the majority of peptides to 8–10 amino acids in
length, longer peptides are known to bind MHC-I (22–28).
Indeed, such “atypically” long peptides can represent up to 10%
of the peptide repertoire bound to MHC-I (29), and are known
to play important roles in aberrant and protective immunity
(30). Such peptides frequently bulge away from the antigen
(Ag)-binding cleft, and can either exhibit substantial flexibility
(23–25, 28) or adopt a more fixed conformation (25, 27, 31).
The extent to which TCRs can accommodate such featured
pMHC-I landscapes is unclear. Presently, TCRs have been
shown to adopt two distinct strategies to ligate bulged pMHC-I
epitopes. Namely, some TCRs can “flatten” the flexible and
bulged peptide to enable an MHC-I-restricted response (32),
whereas others form a more peptide-centric view and make
very limited contacts with the MHC-I molecule (33). It is
unclear whether other mechanisms might enable productive
TCR recognition of atypical pMHC-I landscapes.
The recognition of a 13-amino acid (aa) determinant (LPEP-
LPQGQLTAY, termed “LPEP”) from Epstein-Barr virus,
restricted by HLA-B*35:08, represents a well described exam-
ple of how the T-cell repertoire, isolated from Epstein-Barr
virus individuals (22), responds to a bulged pHLA-I epitope.
Namely, the immune response to HLA-B*35:08LPEP is under-
pinned by biased TCR usage in which the cognate repertoire is
characterized by the dominant selection of TRBV5–6, 6–1, or
7–2 in distinct HLA-B*35:08 donors (33). In addition, the TCR
-chain is highly restricted, with TRAV19*01 and TRAJ34
found in nearly all HLA-B*35:08LPEP-specific TCRs. Previously,
we determined the structure of one prototypical TCR, termed
SB27 (TRAV19*01-TRAJ34*01-TRBV6–1*01) in complexwith
HLA-B*35:08LPEP (33). Here, the SB27 TCR made a limited
footprint on HLA-B*35:08, yet contacted the peptide exten-
sively. The peptide centricity of the interaction was further
emphasized by an alanine-scanning mutagenesis study at the
SB27 TCR-HLA-B*35:08LPEP interface (15). Although the SB27
TCR cross-reacted poorly with the closely related HLA allo-
morph, HLA-B*35:01, it nevertheless, alloreacted with HLA-
B*44:02 (33), which differs from HLA-B*35:08 by 16 amino
acids (supplemental Fig. 1). The TCR - and -chains of the
SB27 TCR mediated many contacts with the bulged viral pep-
tide. How different TCRs with different gene architecture bind
the same HLA-B*35:08LPEP epitope, and how these binding
modes impact their alloreactivity profiles, is unknown.
Here,we assessed the impact ofTCR- and-chain usage on
the recognition of an atypical pHLA-I landscape.We show that
alternate TCR architecture modifies the fine specificity toward
the viral peptide and the pattern of alloreactivity, and canmark-
edly alter the mode of cognate recognition. Notably, a unique
dockingmodewas observed, inwhich theTCRdoes not contact
the prominently exposed region of the viral peptide. Instead,
contacts with HLA-I are maximized via an extremeN-terminal
footprint, which enables the TCR to recognize a distinct feature
of the MHC that has not been observed in previous TCR-
pMHC-I structures.
EXPERIMENTAL PROCEDURES
Analysis of TCRGene Expression—Unbiased amplification of
all expressedTRB orTRA gene products fromT-cell clones was
conducted using template-switch anchored RT-PCRs incorpo-
rating a 3 TRB constant region primer (5-TGCTTCTGATG-
GCTCAAACACAGCGACCT-3) or a 3 TRA constant region
primer (5-AATAGGCAGACAGACTTGTCACTGGA-3),
respectively. Amplicons were subcloned, sampled, Sanger
sequenced, and analyzed as described previously (34).
Cytotoxicity Assay—CTL clones were assayed in duplicate
over a period of 5 h against peptide-pulsed 51Cr-labeled target
cells. The target cells used to generate the data shown in Fig. 1
were HLA-B*35:08 peripheral blood mononuclear cells
expanded with phytohemagglutinin and propagated in IL-2-
containing medium for up to 8 weeks. Percentage of specific
lysis was calculated, and the peptide concentration required for
half-maximum lysis was determined from dose-response
curves. Peptides were synthesized byMimotopes. A  scintilla-
tion counter (Topcount Microplate; Packard Instrument) was
used to measure 51Cr levels in assay supernatant samples. The
mean spontaneous lysis for targets in culture medium was
always 20% and variation around the mean specific lysis was
10%. Normal lymphoblastoid cell lines and the C1R HLA-
deficient mutant lymphoblastoid cell line were also used as tar-
gets, with or without transfection of the gene encoding HLA-
B*44:02 (33).
Intracellular IFN- Staining—CTL clones were tested
against a range of antigen-presenting cells and assayed for
intracellular expression of IFN- by flow cytometry using the
BD Cytofix/Cytoperm kit (BD Biosciences) according to stan-
dard protocols. Briefly, clones were incubated with antigen-
presenting cells at a stimulator to responder ratio of 1:2 for 4 h
in the presence of brefeldinA (BioLegend). For peptide titration
experiments, T2 cells were incubated with various concentra-
tions of LPEP peptide for 1 h and then washed thoroughly prior
to incubation with CTL clones. After stimulation, cells were
stained with Live/Dead Fixable Aqua Dead Cell Stain (Invitro-
gen) and anti-CD8-Cy5.5-PerCP mAb (BioLegend) for 30 min
at 4 °C. Cells were then washed, fixed, permeabilized, and
labeled with anti-IFN--antigen-presenting cell mAb (Bio-
Legend) for 30 min at 4 °C. After a further wash, samples were
collected using a FACSCanto II flow cytometer (BD Biosci-
ences). Data were analyzed with FlowJo software (Tree Star).
Lymphocytes were identified based on light scatter, then live
CD8 T-cells were selected and IFN- gates were drawn
based on unstimulated controls.
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Protein Expression, Refolding, and Purification—The pro-
duction of TCRs and pHLA-I molecules was performed as
described previously (15). Briefly, individual chains of the CA5
and SB47 TCR genes were codon optimized for bacterial
expression and cloned into the pET30 vector. Plasmids con-
taining TCR chains were transformed into Escherichia coli
BL21 cells for expression. Inclusion bodies were isolated and
solubilized in urea buffer (8 M urea, 20 mM Tris-HCl, pH 8, and
1mMDTT) before injecting into refolding buffer. The refolding
procedure lasted 2 days before the samples were dialyzed
against 10 mM Tris buffer (pH 8) three times daily at 4 °C. Dia-
lyzed samples were loaded sequentially onto DEAE cellulose,
size-exclusion, hydrophobic interaction, and anion exchange
columns to obtain pure proteins. Protein size and purity were
assessed by SDS-PAGE.
Thermal Stability Assay—Thermal stability assays of HLA-
B*35:08 mutants in complex with the LPEP peptide were per-
formed with the Real Time Detection instrument (Corbett
RotorGene 300) as described previously (22). The results are
summarized in supplemental Table S1.
Crystallization, Data Collection, and Structure Deter-
mination—TCR-pHLA-I ternary complexes were obtained by
mixing the purified TCR and pHLA-I proteins at a 1:1 molar
ratio. Initial crystallization trials were performed using the
Monash Macromolecular Crystallization Facility Platform.
Optimization trials were conducted via the hanging-drop vapor
diffusion method whereby 1 l of protein and 1 l of the reser-
voir solutions were mixed accordingly. The CA5 TCR-HLA-
B*35:08LPEP complex crystals were obtained at 20 °C, using a
protein concentration of 10 mg/ml in a reservoir solution con-
taining 0.1 M sodium cacodylate (pH 6.7), 0.2 M potassium
iodide, and 16% PEG 3350, with crystals of SB27 TCR-HLA-
B*35:08LPEP as cross-seeds. Crystals of SB47 TCR-HLA-B*35:
08LPEPwere produced at 20 °C, using a protein concentration of
9 mg/ml in a reservoir solution containing 10 mM HEPES (pH
7.5), 0.2 M sodium tartrate, and 12% PEG 10K. Crystals of the
TCR-pHLA-I complexes were soaked with the reservoir solu-
tion with increased percentages of PEG before being flash-fro-
zen in liquid nitrogen. Frozen crystals were taken to the Aus-
tralia Synchrotron, Melbourne, and datasets were collected
with an ADSC-Quantum 315r CCD detector on the MX2
beamline at 100 K. Both datasets were processed and scaled
with theXDS program (35). The structures were determined by
molecular replacement (36) using the published SB27 TCR
(PDB code 2AK4 (33)) and HLA-B*35:08 minus the peptide
(PDB code 1ZHK (22)) as starting search models, whereby the
HLA-I was located initially within the asymmetric unit, fol-
lowed by the TCR. Manual building of the models was con-
ducted with the COOT program (37) and structural refine-
ments were conducted via Phenix (38) and Buster (39) with
maximum-likelihood refinement. The TCRs were numbered
according to the International Immunogenetics Information
System unique numbering system (12), whereby the CDR1
loops start at residue 27, the CDR2 loops start at residue 56, and
the CDR3 loops start at residue 105. The final models were
validated using the Protein Data Bank validationWeb site, and
submitted to the Protein Data Bank database. All molecular
graphic representations were created using PyMol (40).
Surface Plasmon Resonance—Surface plasmon resonance
experiments were conducted using a BIAcore 3000 instrument
at 25 °C with HBS-EP buffer (10 mM HEPES, pH 7.4, and 150
mM NaCl) containing 0.005% surfactant P20 and 1% bovine
serum albumin to prevent nonspecific binding. The conforma-
tion-specific antibody 12H8 (17), which recognizes a confor-
mational epitope within the TCR constant domain, was cou-
pled to the surface of a research grade CM5 sensorchip using a
standard amine-coupling protocol. Approximately 200–400
response units of each TCR (SB27, CA5 and SB47) was coated
onto independent flow cells; the first flow cell was left empty as
a negative control. Various concentrations (0.78–200 M) of
the analytes (either HLA-B*35:01LPEP or HLA-B*35:08LPEP)
were passed over all flow cells. Experimental datawere analyzed
using the BIAevaluation program (version 3.1) assuming the 1:1
Langmuir binding model with drifting baseline to determine
the kinetic constants (Table 1). Using the same protocol, the
HLA-B*35:08LPEPmutantswere flowed over the SB47 and SB27
TCRs at various concentrations (0.78–200 M), and the equi-
librium constant (Kdeq) was determined (supplemental Table
S2). All experiments were performed at least twice (n  2) in
duplicate.
RESULTS
Fine Specificity of the CA5 and SB47 CTL Clones for the LPEP
Peptide—The T-cell repertoire directed against the HLA-B*35:
08-restricted 52LPEPLPQGQLTAY64 (“LPEP”) peptide derived
from the Epstein-Barr virus lyticAgBZLF1 exhibits biasedTCR
-chain usage (TRAV19*01-TRAJ34*01), in which the -chain
is largely germline-encoded, possessing a small N-region that
encodes a highly conserved 94Gly-Phe95 motif (33). In contrast,
the TCR -chain shows greater genetic variability (TRBV5–6,
TRBV6–1, or TRBV 7–2) as well as differing CDR3 usage. For
example, one HLA-B*35:08 CTL clone, termed CA5, uses the
sameTCR-chain andTRBV6–1*01 gene segment as the SB27
TCR, but a different J gene segment (TRBJ1–1) (33). Conse-
quently, their respective CDR3 loops differ markedly,
whereby the CDR3 loop of the CA5 TCR (CASPGETEAF) is
shorter than that of the SB27TCR (CASPGLAGEYEQY). Inter-
estingly, whereas the TRAV19*01-TRAJ34 -chain dominated
the CTL response toHLA-B*35:08LPEP, one CTL clone (termed
SB47) exhibited a completely unique TCR architecture
(TRAV39*01-TRAJ33-TRBV5–6*01-TRBJ2–7) (33). Accord-
ingly, the SB27, CA5, and SB47CTL clones enabled us to exam-
ine the impact of CDR3 variability and TCR gene usage on the
response to HLA-B*35:08LPEP.
Previously, we demonstrated that the central region of the
LPEPpeptide (P4–P8) is critical for SB27TCR recognition (33).
To gain a detailed understanding of the fine specificity require-
ments of the CA5 and SB47 clones toward HLA-B*35:08LPEP,
we performed cytotoxicity assays with single site substitutions
along the solvent exposed residues of the LPEP peptide, using
the SB27 clone as a control (Fig. 1). Each solvent-exposed posi-
tion along the length of the peptide was mutated to one of 6
residues (Gly/Ala, Ser, Val, Lys, Asp, and Tyr). As expected
from the crystal structure of the SB27 TCR-HLA-B*35:08LPEP
complex and previous fine specificity analyses (33), the SB27
clone showed negligible sensitivity toward substitutions at
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positions P9–P12, some sensitivity toward substitutions at P1,
P3, P5, and P8, and substantial sensitivity toward substitutions
at P4, P6, and P7. Overall, the fine specificity of the CA5 clone
mirrored that of the SB27 clone, with substitutions at the
N-terminal region of the epitope exhibiting a greater effect.
Nevertheless, differences in the fine specificity patterns were
observed. Namely, whereas the SB27 clone tolerated the sub-
stitution of P8-Gly to Val or Asp, these replacements were
not tolerated by the CA5 clone (Fig. 1). In addition, the CA5
clone showed a heightened sensitivity at P4–P7 in compar-
ison to the SB27 clone. Accordingly, differing CDR3 usage
subtly affects the fine specificity profiles of the SB27 and
CA5 clones.
Next, we examined the fine specificity of the SB47 clone
toward the LPEP peptide. Substitutions at P7–P12 did not
greatly impact on SB47 recognition, and a number of substitu-
tions at P6were also tolerated (Fig. 1). Thus, the SB47 clonewas
more tolerant to P6–P7 substitutions compared with the SB27
and CA5 clones. Additionally, the SB47 clone was considerably
more sensitive at P1 and P5 compared with the SB27 and CA5
clones. These observations suggest that the fine specificity pro-
file of the SB47 clone for the LPEP peptide is moreN terminally
focused than that of the SB27 and CA5 clones, in turn suggest-
ing fundamentally different docking modes.
The Impact of HLA Polymorphism on T-cell Specificity—The
HLA-B*35:01/08 molecules differ only by a single residue,
which is buried inside the Ag-binding cleft (Arg156 and Leu156
in HLA-B*35:08 and HLA-B*35:01, respectively (supplemental
Fig. S1)). To dissect the fine preferences for MHC restriction
exhibited by the CA5 and SB47 TCRs, we compared reactivity
of the CA5 and SB47 CTL clones toward HLA-B*35:08 and
HLA-B*35:01 targets presenting the LPEP peptide (Fig. 2).
Although the CA5 CTL clone recognized both HLA allo-
morphs when high peptide concentrations were added, it pref-
erentially recognized HLA-B*35:08LPEP when the peptide was
limited (Fig. 2A), in a similar manner to the SB27 clone. Next,
we undertook surface plasmon resonance analysis of the
recombinant CA5 and SB27 TCRs to establish their affinities
for HLA-B*35:08LPEP and HLA-B*35:01LPEP (Fig. 2B and sup-
plemental Fig. S2). The affinity values obtained for the SB27
TCR were consistent with those published previously (Table 1)
(33), with a 4-fold decrease in the affinity for HLA-B*35:01LPEP
(Kdeq 52.25 4.88M) compared with theHLA-B*35:08LPEP
complex (Kdeq 12.15 0.35M). The affinity of theCA5TCR
toward HLA-B*35:08LPEP (Kdeq 3.75 0.01M) was4-fold
higher than that of the SB27 TCR (Kdeq  12.15  0.35 M),
which was attributable to faster association and slower dissoci-
ation constants (CA5: kon  50.80  8.06 104 M1 s1, koff 
0.19  0.02 s1; SB27: kon  10.05  0.92 104 M1 s1, koff 
0.11  0.01 s1) (Table 1). In agreement with the cytotoxicity
data, the affinity of the CA5 TCR toward HLA-B*35:01LPEP
(Kdeq  27.10  0.42 M) was notably weaker compared with
HLA-B*35:08LPEP, which was due to slower association and
faster dissociation rates upon HLA-B*35:01LPEP binding (Fig.
2B, supplemental Fig. S2, and Table 1). Accordingly, the SB27
and CA5 TCRs exhibited similar patterns of cross-reactivity
between HLA-B*35:01/08LPEP, although the CA5 TCR bound
with higher affinity to these HLA allomorphs.
In contrast to the SB27 and CA5 CTLs, the SB47 clone rec-
ognized the LPEP peptide presented by HLA-B*35:08 and
HLA-B*35:01 equally well (Fig. 2C). To assess whether the
FIGURE 1. Antigen specificity of the SB27, CA5, and SB47 TCRs. Dose-re-
sponse analysis of LPEP peptide analogues carrying single amino acid substi-
tutions was conducted using chromium release assays to assess recognition
by the SB27, CA5, and SB47 CTL clones. Peptide concentrations required to
reach half-maximal lysis are shown. Some of the experiments with the SB27
clone were published previously and are shown here for comparison (33).
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affinity of the SB47 TCR was affected by the HLA-B*35:01/08
polymorphism, we quantified SB47 TCR binding to HLA-B*35:
08LPEP and HLA-B*35:01LPEP. The affinity of the SB47 TCR for
HLA-B*35:08LPEP (Kdeq  25.00  0.28 M) was lower com-
pared with the CA5 and SB27 TCRs, which was due to a faster
dissociation rate (koff  0.30  0.01 s1) (Table 1). Further-
more, in contrast to the SB27 and CA5 TCRs, the SB47 TCR
bound the HLA-B*35:08LPEP and HLA-B*35:01LPEP (Kdeq 
29.25  0.07 M) complexes with similar affinities (Fig. 2D,
supplemental Fig. S2, and Table 1). These findings are consis-
tent with the functional data indicating that the SB47 TCR
could not discriminate between the two closely related HLA-
B35 allomorphs when bound to the LPEP peptide.
Unique Alloreactivity Footprints Across Clonotypes—The
SB27CTL clone alloreactswithHLA-B*44:02 presenting one or
more unknown self-peptide(s) (Fig. 2E)(33). HLA-B*35:08 and
HLA-B*44:02 differ by 16 residues, three ofwhich (positions 80,
83, and 167) are solvent exposed (supplemental Fig. S1), yet are
not involved in the SB27 TCR-HLA-B*35:08LPEP interaction.
Moreover, HLA-B*35:08 and HLA-B*44:02 are structurally
very similar (rootmean square deviation of theAg-binding cleft
is 0.4 Å), suggesting that the SB27 TCR could potentially bind
both pHLA-I molecules with a similar docking mode. Next, we
assessed whether the CA5 and SB47 clones could alloreact with
HLA-B*44:02, using a CTL lysis assay against allogeneic cells in
the absence of exogenous peptide. Surprisingly, the CA5 CTL
clone did not alloreact with HLA-B*44:02 (Fig. 2E). Given that
the CA5 and SB27 TCRs differ only in the CDR3 loop, which
forms dominant interactions with peptide in the SB27 TCR-
HLA-B*35:08LPEP complex, this indicates that the observed dif-
ferences in alloreactivity patterns are driven by peptide-centric
interactions.
Similarly the SB47 clone did not alloreact with HLA-B*44:02
presenting self-peptides (Fig. 2F). However, the SB47 CTL
FIGURE 2. Cross-reactivity of the SB27, CA5, and SB47 TCRs. A and C, CD8 T-cell activation was measured by intracellular cytokine staining for IFN after
stimulationwith peptide-pulsed T2 cells expressing either HLA-B*35:08 or HLA-B*35:01 as indicated. Experiments were performed twicewith similar results. B
andD, surface plasmon resonance experiments showingCA5 (B) and SB47 (D) TCRbinding toHLA-B*35:08 andHLA-B*35:01 presenting the LPEPpeptide. Data
represent the concentration versus response unit curve derived from two experiments. E and F,HLA-restricted recognition and alloreactivity of the SB27, CA5,
and SB47 CTL clones. E, specific lysis of target cells expressing different HLAmolecules by SB27 and CA5 CTLs. TheHLA cell line C1Rwas included as a control.
F, activation of CA5 and SB47 CTLs after stimulation with T2 cells expressing HLA-B*35 allomorphs, parental C1R cells, or C1R cells expressing HLA-B*44:02.
TABLE 1
Surface plasmon resonance experiments for HLA-B35LPEP and the CA5, SB27, and SB47 TCRs
The experiments were conducted at least twice (n 2) in duplicate and the values represent the mean S.E.
Immobilized TCR Analyte Kdeq Kon Koff t1⁄2a Kdcalc
M  104 M1 s1 s1 s M
CA5 HLA-B*35:08LPEP 3.75 0.01 50.80 8.06 0.19 0.02 3.62 0.32 3.78 0.95
SB27 HLA-B*35:08LPEP 12.15 0.35 10.05 0.92 0.11 0.01 6.21 0.55 11.14 0.03
SB47 HLA-B*35:08LPEP 25.00 0.28 15.05 5.16 0.30 0.01 2.33 0.05 19.77 6.75
CA5 HLA-B*35:01LPEP 27.10 0.42 34.45 6.01 0.67 0.16 1.07 0.26 19.38 1.34
SB27 HLA-B*35:01LPEP 52.25 4.88 NDb NDb NDb NDb
SB47 HLA-B*35:01LPEP 29.25 0.07 15.50 0.03 0.33 0.04 2.15 0.24 20.9 1.99
a t1⁄2 0.693/Kdeq.
bND, not determined.
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clone did alloreact with HLA-B*35:01. This alloreactivity
appeared to be dependent on one or more self-peptide(s) pro-
cessed and presented independently of the transporter associ-
ated with antigen processing because the transporter associ-
ated with the antigen processing-deficient T2 cell line,
transfected to express HLA-B*35:01, was recognized. In con-
trast, SB47 failed to recognize T2 cells transfected to express
self-HLA-B*35:08. Given that the SB47 CTL clone did not dis-
tinguish between HLA-B*35:08 and B*35:01 presenting the
LPEP viral peptide, this indicates that the nature of the
self-peptide(s) dictates the HLA-B*35:01 alloreactivity. Accord-
ingly, similar to the cognate interaction, the extent of alloreactivity
across the three CTL clones is determined via a peptide-centric
mechanism.
Structure of the CA5 TCR-HLA-B*35:08LPEP Complex—To
understand how the CA5 TCR ligated to HLA-B*35:08LPEP, we
determined its ternary complex and compared it to the SB27
TCR-HLA-B*35:08LPEP complex (Fig. 3). The structure of
the CA5 TCR-HLA-B*35:08LPEP complex was solved at
2.3-Å resolution and refined to Rfactor/Rfree values of 20.5 and
25.7%, respectively (Table 2). Unambiguous electron density
was observed at the CA5 TCR-HLA-B*35:08LPEP interface
(supplemental Fig. S3, A and B). In contrast to the SB27 TCR-
HLA-B*35:08LPEP structure, in which two different orienta-
tions of the SB27 TCR were observed in the crystal lattice, the
CA5 TCR-HLA-B*35:08LPEP complex crystallized in a different
space group, and only one ternary complex was present in the
asymmetric unit.
The CA5 TCR-HLA-B*35:08LPEP complex overlaid closely
with the SB27 TCR-HLA-B*35:08LPEP complex (root mean
square deviation of 1.65 Å over the entire complex) (Fig. 3, A
and B). As such, the CA5 TCR docked orthogonally (93°) to the
long axis of the binding cleft ofHLA-B*35:08 (Fig. 3B). The total
buried surface area (BSA) at the CA5 TCR-HLA-B*35:08LPEP
interface (	 1800 Å2) was similar to that of the SB27 TCR-
HLA-B*35:08LPEP interface (	 1900 Å2), and the total number
of contacts at the respective interfaces was similar (CA5 TCR:
142 van derWaals, 13 hydrogen bonds; SB27 TCR: 137 van der
Waals, 16 hydrogen bonds, and 1 salt bridge). Moreover, the
contributions from each of the CDR loops at the respective
interfaces were similar, with the CDR1, -2, and -3 loops of
the CA5 TCR contributing 13.0, 18.4, and 32.9% of the total
BSA, respectively, and the CDR1, -2, and -3 loops of the
CA5 TCR contributing 17.5, 1.7, and 15.6% of the total BSA,
FIGURE 3. Overview and structural footprints of the SB27, CA5, and SB47 TCRs. Overview (upper panels) of the SB27 (A), CA5 (B), and SB47 (C) TCRs
bound to HLA-B*35:08 (white) presenting the LPEP peptide (black). The color scheme is consistent across all panels and the orientation of HLA-B*35:08
is identical. TCR - and -chain framework residues are colored in pale pink and cyan, respectively. CDR1, purple; CDR2, green; CDR3, red; CDR1,
yellow; CDR2, sand; CDR3, orange. The structural footprints (lower panels) of the SB27 (A), CA5 (B), and SB47 (C) TCRs onto HLA-B*35:08LPEP are shown
as surface representation with atoms colored based on the corresponding CDR loops that mediate the contacts. The black spheres represent the center
of mass for the V and V domains.
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respectively. Accordingly, consistent with the biased
TRAV19*01-TRAJ34*01 usage, the -chain of the CA5 TCR
dominated the interface (BSA 64.3%).
Akin to the SB27 TCR, the CA5TCR adopted the same “pep-
tide-centric” docking onto theHLA-B*35:08LPEP complex, with
50% of the BSA at the interface arising from the bulged pep-
tide (Fig. 3B), which markedly contrasts with typical TCR-
pMHC interactions involving peptides of canonical length
(BSA 20%) (41). Furthermore, similar to the SB27 TCR interac-
tion, the CA5 TCR did not deform the bulged peptide upon
ligation, and the conformation of the peptide in the SB27 TCR
and CA5 TCR ternary complexes was very similar. Within the
CA5 and SB27 TCR complexes, the TCR-peptide interaction
was mediated primarily via the CDR3 and CDR1 loops (15)
(Fig. 4A). Specifically, the CDR1 loop of the CA5 and SB27
TCRs ran parallel to the bulged Ag, forming extensive interac-
tions with residues from P6 to P9 of the peptide, whereas the
CDR3 loops flanked primarily the ascending region of the
LPEP peptide between residues P4 to P7 (Fig. 4A).
Despite the overall similarities between the CA5 TCR-HLA-
B*35:08LPEP and SB27 TCR-HLA-B*35:08LPEP complexes, dif-
ferences within the interfaces were apparent. First, the shape
complementarity (42) at theCA5TCR-HLA-B*35:08LPEP inter-
face (shape complementarity  0.77) was moderately higher
than that of the corresponding SB27TCR interface (shape com-
plementarity 0.71), which correlated with the higher affinity
of the CA5 TCR toward HLA-B*35:08LPEP. Second, in compar-
ison to the SB27 TCR footprint, the CA5 TCR docked slightly
differently onto HLA-B*35:08LPEP, with the most notable con-
sequence being that the CA5 TCR did not directly contact any
residues from the 1-helix of HLA-B*35:08 (Fig. 3B). Although
the SB27 TCR contacts two positions on the 1-helix (65 and
69) (Fig. 3A), previous mutagenesis studies on the SB27 TCR-
HLA-B*35:08LPEP complex underscore the observation that the
1-helix of HLA-B*35:08 does not appreciably contribute to
the TCR-HLA-B*35:08LPEP interface of either the SB27 or CA5
TCRs (Fig. 3B). Conversely, residues within the 2-helix of
HLA-B*35:08 define an energetic hot spot that underpins SB27
TCR recognition (15). Given that these residues, namely
Arg151, Gln155, Arg157, and Ala158, are also contacted by the
CA5 TCR, this suggests that a common hot spot within the
2-helix of HLA-B*35:08 drives the association with the SB27
and CA5 TCRs (supplemental Table S3, Fig. 4C).
CDR3 Loop-mediated Interactions—The SB27 and CA5
TCRs differ in their CDR3 loops (CA5 TCR, CASPGETEAF;
SB27 TCR, CASPGLAGEYEQY), and the interactions medi-
ated by this loop varied accordingly between the two ternary
complexes. Within the SB27 TCR-HLA-B*35:08LPEP complex,
the CDR3 loop contacted the peptide and the 2-helix of
HLA-B*35:08. Pro95 solely interacted with the peptide, con-
tacting the P7-Gln and P8-Gly residues located at the top of the
bulged peptide (Fig. 4B). The SB27CDR3-HLA-B*35:08 inter-
actions principally arose fromLeu98 forming a large number of
van der Waals contacts with HLA-B*35:08 and Glu101 salt
bridging to Arg151. Although the conformation of the N-termi-
nal region (104CASPG108) in the CA5 TCR CDR3 loop over-
laid closely with the corresponding region of the SB27 CDR3
loop, the remainder of the CDR3 loop adopted a markedly
different conformation and, as a consequence, the CDR3-
HLA-B*35:08 interactions differed (Fig. 4B). Namely, the salt
bridge with Arg151 was absent in the CA5 TCR ternary com-
plex; instead, Arg151 formed van der Waals contacts with
Thr110 (Fig. 4C). Additionally, Leu98 in the SB27 TCR was
replaced by Glu109 in the CA5 TCR, whose side chain orien-
tated away from the interface (Fig. 4D), with its aliphaticmoiety
packing against Ala150 and Arg151 (Fig. 4, B and C). As a conse-
quence, although the CA5 Glu109 did not directly contact the
bulged peptide, its close proximity with P8-Gly (Fig. 4D) may
explain why the CA5 CTL clone was more sensitive to P8 sub-
stitutions than the SB27 CTL clone (Fig. 1).
TABLE 2
Data collection and refinement statistics
Structure CA5 TCR-HLA-B*35:08LPEP SB47 TCR-HLA-B*35:08LPEP
Resolution (Å)a 19.8-2.3 (2.5-2.3) 168-2 .8 (2.9-2.8)
Space group P21 I4
Temperature 100 K 100 K
Unit-cell parameters (Å) 55.10, 78.41, 105.34 237.60, 237.60, 61.20
(°)  93.06
No. observations 253,487 (56298) 299,703 (31899)
No. unique reflections 39,873 (8770) 42,851 (4208)
Completeness (%) 99.8 (100) 99.9 (100)
Rmergeb (%) 10.0 (42.5) 14.5 (47.6)

I/s(I) 13.2 (3.98) 9.59 (3.45)
Multiplicity 6.3 (6.4) 7.0 (7.5)
Refinement statistics
Non-hydrogen atoms
Protein 6727 6707
Water 132 124
Rfactor c(%) 20.5 20.0
Rfree (%) 25.7 23.3
Root mean square deviations from ideality
Bond lengths (Å) 0.008 0.012
Bond angles (°) 1.08 1.21
Ramachandran plot (%)
Most-favored region 91.2 91.4
Allowed region 8.2 8.4
Generously allowed region 0.4 0.2
a Values in parentheses represent the highest-resolution shell.
bRmergeIhkl 
Ihkl /Ihkl.
c Rfactor hkl Fo Fc/hklFo for all data except 5%, which were used to calculate Rfree.
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Overview of the SB47 TCR-HLA-B*35:08LPEP Complex—To
understand the shifted fine specificity profile of the SB47 TCR
(Fig. 1), we determined the crystal structure of the SB47 TCR-
HLA-B*35:08LPEP complex. The structure was solved to 2.8-Å
resolution and refined to Rfactor/Rfree values of 20.0 and 23.3%,
respectively (Table 2). Unambiguous electron density was
observed at the SB47 TCR-HLA-B*35:08LPEP interface (supple-
mental Fig. S3, C and D).
The SB47 TCR bound orthogonally onto HLA-B*35:08LPEP
with a docking angle of87° (Fig. 3C), similar to the orientation
of the CA5 and SB27 TCRs ligated to HLA-B*35:08LPEP (Fig. 3).
However, in stark contrast to the CA5 and SB27 TCRs docking
modes, the SB47 TCRwas positioned toward the very N-termi-
nal end of the HLA-B*35:08 Ag-binding cleft, thereby essen-
tially not contacting the prominent apex of the super-bulged
peptide.
The total BSA at the SB47 TCR-HLA-B*35:08LPEP interface
was	2000 Å, moderately higher than the BSA of the SB27 and
CA5 TCR-HLA-B*35:08LPEP complexes, yet nevertheless,
within the range of TCR-pMHC-I interactions determined to
date (5). The greater BSA was consistent with an increased
number of interactions observed at the SB47 TCR-HLA-B*35:
08LPEP interface (168 van der Waals, 16 H-bonds, and 3 salt
bridges) compared with the respective CA5 and SB27 TCR-
HLA-B*35:08LPEP interfaces. However, unlike the centrally
docked SB27 andCA5TCRs, whichmade limited contacts with
HLA-B*35:08, the extreme N-terminal positioning of the SB47
TCR allowed extensive interactions with the HLA-I molecule
itself. Indeed, at this interface, the SB47 TCR interacted with
the 1- and 2-helices (spanning residues 55–68 and 162–170,
respectively). Consequently, the SB47 TCR-HLA-B*35:08
interactions (BSA 83%) were more prominent than the SB47
TCR-peptide contacts (BSA 17%) (Fig. 3C). Nevertheless,
despite this more extensive HLA footprint, the affinity of the
SB47 TCR for HLA-B*35:08LPEP was weaker than that of the
CA5 and SB27 TCRs (Table 1).
FIGURE 4.Contacts between the CA5 TCR and theHLA-B*35:08LPEP complex. A, CA5 TCR-peptide interactionsweremediated primarily via the CDR3 (red)
andCDR1 (yellow) loops. B, structural superposition of theCDR3 loops of theCA5TCR (orange) and SB27 TCR (transparent cyan) in the corresponding ternary
complexes. The conserved TCR-peptide interaction, with the peptide in black stick, is highlighted and the specific TCR-HLA interaction mediated by the CA5
TCR is comparedwith theSB27TCR.C, conservedTCR-HLA interactionsobserved in theCA5andSB27 ternary complex structures.D, top viewof theCDR3 loop
interaction with the HLA-B*35:08LPEP complex for the CA5 TCR (orange) superposed with the SB27 TCR (transparent cyan). This view shows the difference in
orientationbetween theGlu109 and Leu98 side chains in theCA5 and SB27 TCRs, respectively. All structural representations follow the color schemedepicted
in Fig. 3. Blue dashed lines represent van der Waals interactions; red dashed lines represent hydrogen-bond contacts; spheres represent the C atom of glycine
residues.
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A New Footprint on HLA-I—As exemplified by the SB27 and
CA5 TCR-HLA-B*35:08LPEP complexes, a bulged and rigid
peptide bound within the Ag-binding cleft acts a “hurdle” for
the TCR to dock extensively onto the HLA itself. However, the
SB47 TCR overcomes this hurdle by adopting a markedly
shifted N-terminal footprint, whose center of gravity differs
markedly (by 18 Å) compared with that of the SB27 TCR.
Indeed, due to its extreme N-terminal footprint, the SB47 TCR
did not contact position 155 of HLA-B*35:08 (Fig. 3C), a posi-
tion that represents a TCR contact point in all TCR-pMHC-I
structures determined to date (5, 14).
Five of six SB47 CDR loops contacted HLA-B*35:08 (Fig.
3C, supplemental Table S4), with the CDR3 and CDR3
loops contributing most extensively to the interface (19.5
and 39.7% of the total BSA, respectively). Remarkably, only
one HLA-B*35:08 contact point was shared between the
SB47 and CA5 TCRs (Gly162), and the SB47 and SB27 TCRs
(Gln65); moreover, different CDR loops were involved in
these contacts (supplemental Table S4). The SB47 -chain
(BSA 44%) contacted both helices of HLA-B*35:08 (Fig. 3C).
The role of the CDR1 loop (BSA 8.7%) was limited to Asp37
salt bridging to Arg170, and forming van der Waals contacts
with Trp167 (Fig. 5A). A stretch of residues, 57LSN59, from the
CDR2 loop (BSA12.2%), contactedGly162, Leu163, andGlu166,
the latter of which interacted with the framework residue,
Thr82 (Fig. 5A). TheCDR3 loop formed an extendednetwork
of interactions with HLA-B*35:08, with its loop positioned
orthogonally to the main axis of the 1-helix, contacting resi-
dues spanning positions 55 to 61, as well as interacting with
Trp167 and Arg170 of the 2-helix (Fig. 5B). Of note, residues
55–57 of HLA-B*35:08 form a turn before the start of the
1-helix, and this region of the HLA-I has not been contacted
by any TCR determined to date (Fig. 5B) (5).
The SB47 -chain (BSA 56%) exclusively contacted the
1-helix via its CDR2 (BSA 8.6%) and CDR3 loops (supple-
mental Table S4). The interactions mediated via the CDR2
loop involved Tyr57 and Glu58, as well as two framework
(FW) residues upstream of CDR2, namely Arg66 and Gln67
(Fig. 5C). The CDR2/FW interaction spanned from Pro57 to
Lys68 and involved a number of van derWaals interactions and
FIGURE 5. Contacts between the SB47 TCR and the HLA-B*35:08LPEP complex. A, the germline-encoded SB47 V chain, including CDR1, CDR2, and
framework residues, interacted extensively with the 2-helix of HLA-B*35:08. B, the CDR3 loop bridged between the 1- and 2-helices, contacting a loop
region fromGlu55 to Pro57 of HLA-B*35:08. C, the CDR2 loop and its neighboring framework residues sat directly above the N-terminal part of the 1-helix of
HLA-B*35:08,makingcontactsbetweenPro57 andLys68.D, theCDR3 loopcontacteda small stretchof the1-helix ofHLA-B*35:08, includingGln65. E, theSB47
TCR interactedwith the N-terminal region of the peptide, including P1-Leu and P4-Pro to P8-Gly, exclusively via the CDR3 loop. All structural representations
follow the color scheme depicted in Fig. 3. Blue dashed lines represent van derWaals interactions; red dashed lines represent hydrogen-bond contacts; spheres
represent the C atom of glycine residues.
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two salt bridges (Lys68 with Glu58 and Asp61 with Arg66) (Fig.
5C). The CDR3 loop was wedged between the ascending part
of the bulged peptide (P4–P7) and Arg62 of the 1-helix. The
non-germline-encoded residues Thr109 and Gly110 made van
der Waals contacts with Gln65/Asp61 and Arg62/Ile66, respec-
tively (Fig. 5D). The majority of the interactions between the
CDR3 loop and the 1-helix were focused around Arg62,
whose side chain was flanked by the main chain of the CDR3
loop and Tyr113 (Fig. 5D). Collectively, the SB47 TCR adopted
a markedly contrasting footprint onto HLA-B*35:08 compared
with the SB27 and CA5 TCRs. This extreme N-terminal foot-
print is reminiscent of the way in which some autoreactive
TCRs dock onto MHC-II (supplemental Fig. S2) (43–45),
although N-terminal docking footprints have also been
observed for antimicrobial TCR-pMHC-I complexes (13).
To investigate further the importance of the N-terminal
region of HLA-B*35:08 for SB47 TCR recognition, we per-
formed alanine scanning mutagenesis in conjunction with sur-
face plasmon resonance analyses. Of the N-terminal HLA-
B*35:08 residues involved in the interactionwith SB47 TCR, we
mutated the following to alanine: Glu55, Asp61, Arg62, Ile66,
Leu163, Glu166, and Arg170. We also included two control resi-
dues, namely Arg151 and Gln155, as they are not contacted by
the SB47 TCR, yet they are important for SB27 TCR recogni-
tion (15). First, we tested the stability of eachmutant via a ther-
mal shift assay; only the I66A mutant decreased the stability of
the pHLA-I complex significantly (bymore than 10 °C) (supple-
mental Table S1) (22). Next, we performed surface plasmon
resonance analyses against the panel of HLA-B*35:08LPEP
mutants (supplemental Table S2). The I66A mutant impacted
on SB47 and SB27 TCR recognition, despite the absence of
direct contacts with the SB27 TCR. This effect is most likely
indirect, with Ile66 being important for maintaining pMHC
structural integrity. The control mutations, including Arg151
and Gln155, both exhibited decreased affinities with the SB27
TCR yet had minimal impact on SB47 TCR recognition (sup-
plemental Table 2A). The six other HLA-B*35:08 mutants all
decreased SB47 TCR binding affinity by more than 7-fold, with
minimal effects on SB27 TCR affinity (supplemental Table S2,
Fig. 6). The energetic footprint of the SB47 TCR is in marked
contrast to the corresponding energetic footprint for the SB27
TCR (15) (Fig. 6). Collectively, the mutagenesis data not only
highlight the N terminally focused nature of the SB47 TCR but
also, for the first time, illustrate the importance of theGlu55 and
Asp61 HLA residues in enabling TCR recognition.
New TCR Footprint on the Bulged Peptide—Due to the dis-
tinct SB47 TCR footprint, its interaction with the bulged pep-
tide differed from that of the SB27 and CA5 TCRs. Namely, the
SB47 TCR formed limited contacts with the LPEP peptide,
mediated exclusively via the CDR3 loop (Fig. 5E). The CDR3
loop sequence, 108RTGSTYE114, contacted the N-terminal part
of the peptide, P1-Leu and P4-Pro, as well as the ascending part
of the super-bulge, fromP5-Leu to P8-Gly (Fig. 5E). The P1-Leu
residue interactedwithTyr113, and P4-Pro contacted themain
chain of Gly110-Ser111, thereby providing a basis for the
decreasedCTLactivity observedwhen these twopositionswere
substituted in the LPEP peptide (Fig. 1). The interactions span-
ning P5-Leu to P8-Gly were mostly featured by main chain
interactions arising either from the peptide or the CDR3 loop,
with three H-bonds (Arg108NH2 to P6-ProO, P7-GlnO, P8-Gly;
Gly110O to P5-LeuN; Ser111O to P5-LeuO, P6-ProO) helping
to drive the specificity of this interaction. Additionally, the
P5-Leu side chain packed against Arg108 and themain chain of
the CDR3 loop. The P7-Gln and P8-Gly residues were mostly
solvent exposed (Fig. 5E), thereby providing a basis for under-
standing why the SB47 TCR was tolerant to substitutions at
these positions. Thus, by adopting an extreme N-terminal
FIGURE 6. Energetic footprints of the SB27 and SB47 TCRs on the HLA-B*35:08LPEP complex. A and B, surface representation of HLA-B*35:08 (white) with
the LPEP peptide (pale purple). The energetic footprint is colored accordingly to the importance of each residue, with critical residues in red (Kdeq decrease
5-fold); important residue inorange (5-foldKdeqdecrease3-fold);dark gray indicates residues thatwerenot important for the interaction.Panel A shows the
SB27 TCR energetic footprint, and panel B shows the SB47 TCR energetic footprint. The CDR loops are represented in schematic format and colored according
to the scheme used in Fig. 3.
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docking mode on HLA-B*35:08, the SB47 TCR does not con-
tact the most prominent feature of the bulged peptide.
DISCUSSION
The circulating TCR repertoire encompasses enormous
diversity and enables adaptive immune responses to a universe
of different pMHC complex antigens. For peptides of canonical
length (8–10 residues) presented by MHC-I, a portrait of how
closely related and distinct TCRs can interact with the same
pMHC epitope has been established (5). In particular, for
V8.2 TCRs, which are arguably the most intensively investi-
gated (4), approximate common TCR-pMHC docking modes
have prevailed, thereby suggesting a basis for MHC bias that
largely arises from conserved germline-encoded interactions
between the CDR2 loop and a given region of the MHC (46,
47). A wider range of docking footprints atop the same pMHC
landscape is apparent when distinct TCR - and/or -chain
usage is considered (13, 16, 48). Previously, we provided insight
into how the T-cell repertoire can accommodate atypical pep-
tides (10 amino acids in length) bound to theMHC-I (32, 33).
Two divergent TCR recognition modes were apparent. In one
mode, the bulged peptide was flattened to enable a large and
“standard” MHC footprint (32). In the other mode, a predomi-
nantly peptide-centric interaction with a rigid bulged peptide
resulted in a very limited MHC-I footprint (33). Here, we pro-
vide structural and mechanistic data to explain how both
closely related and distinct TCRs can interact with a “super-
bulged” peptide presented by HLA-I.
The CA5 TCR is encoded by the same TRAV-TRAJ-TRBV
gene combination as the archetypal SB27 TCR, with the differ-
ences being confined to their respective CDR3 loops. Accord-
ingly, the overall TCR-HLA-B*35:08LPEP footprints were simi-
lar. The SB27 TCR made limited contacts with the 1- and
2-helices of HLA-B*35:08. Nonetheless, the footprint was
even more restricted with the CA5 TCR, which does not con-
tact the 1-helix. Accordingly, despite a consensus docking
mode between these two TCRs, the non-germline-encoded
CDR3 loop affected MHC-driven contacts, whereas essen-
tially preserving the extent of the peptide-TCR interactions.
This highlights the peptide-centricity of this particular TCR-
pMHC-I interaction and makes generalizations, such as two-
step binding modes and exclusive germline-encoded MHC
bias, difficult to reconcile in this system (49). Intriguingly,
whereas the SB27 and CA5 TCRs both preferentially recog-
nized HLA-B*35:08LPEP over HLA-B*35:01LPEP, they neverthe-
less, showeddifferent patterns of alloreactivity. Indeed, only the
SB27 TCR alloreacted with HLA-B*44:02. Given the close
structural homology between HLA-B*35:08 and HLA-B*4402,
and the peptide-centric focus of these TCRs, these data suggest
that peptide-centric molecular mimicry defines HLA-B*44:02
alloreactivity for the SB27 TCR and that the nature of theHLA-
B*44:02-restricted self-peptide is non-permissive for CA5 TCR
binding. In line with this view, fine specificity differences
between SB27 TCR and the CA5 TCR with regard to the cog-
nate LPEP peptide were also apparent.
Additionally, we determined the structure of a TCR that pos-
sessed markedly different TRAV-TRAJ-TRBV gene usage in
comparison to the SB27 and CA5 TCRs, yet nevertheless, rec-
ognized the same HLA-B*35:08LPEP complex. Remarkably, the
SB47 TCR employed a peculiar and unprecedented binding
mechanism to accommodate the bulged LPEP epitope.Namely,
by establishing an extensive footprint on the extreme N-termi-
nal end of HLA-B*35:08, the SB47 TCR essentially circum-
vented the most prominent feature of the bulged epitope. The
CDR3 loop and, to a lesser extent, the CDR3 loop, domi-
nated contacts with HLA-B*35:08LPEP, with the docking mode
enabling a more HLA-centric view in comparison to the SB27
and CA5 TCRs. Moreover, the markedly shifted N-terminal
footprint enabled the TCR to contact a region of MHC-I that
had not been observed previously to mediate contacts with a
TCR.Notably, this docking strategy also obviatedTCRcontacts
with Gln155 from HLA-B*35:08, which is surprising given that
position 155 has been contacted in every TCR-pMHC-I com-
plex reported to date (5). The N-terminal docking mode
explains why the SB47 TCR was able to bind both HLA-B*35:
08LPEP and HLA-B*35:01LPEP, as the point of difference
between these two allomorphs resides within the 2-helical
hinge, a region that is not contacted in the corresponding ter-
nary complex. Although the SB47 TCR did not alloreact with
HLA-B*44:02 and was not activated by HLA-B*35:08 present-
ing self-peptides, it nevertheless, alloreacted with HLA-B*35:
01. Intriguingly, this implicates differences in the repertoire or
conformation of self-peptides bound to HLA-B*35:01 versus
HLA-B*35:08 in the HLA-B*35:01 alloreactivity of this TCR.
In summary, our data demonstrate that alternative TCR
structures with unanticipated dockingmodes can contribute to
T-cell-mediated immune recognition of a lengthy and rigid
viral peptide bound to MHC-I. These unusual strategies not
only illustrate the versatility of the T-cell repertoire, but also
shape our understanding of MHC restriction and TCR
alloreactivity.
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